Immunosuppressive drugs impairs antibody response of the polysaccharide and conjugated pneumococcal vaccines in patients with Crohn's disease

Vaccine

Volumn 33, Issue 41, 2015, Pages 5464-5469

  Kantsø, Bjørn ^a   Halkjær, Sofie Ingdam ^b   Thomsen, Ole Østergaard ^c   Belard, Erika ^c   Gottschalck, Ida Benedikte ^c   Jørgensen, Charlotte Sværke ^a   Krogfelt, Karen A ^a   Slotved, Hans Christian ^a   Ingels, Helene ^a   Petersen, Andreas Munk ^b  

^a STATENS SERUM INSTITUT   (Denmark)

^b HVIDOVRE HOSPITAL   (Denmark)

^c GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

13 Valent conjugated pneumococcal vaccine; 23 Valent pneumococcal polysaccharide vaccine; Crohn's disease; Inflammatory bowel disease; Pneumococcus; Vaccination

Indexed keywords

ADALIMUMAB; ANTIBODY; AZATHIOPRINE; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; MERCAPTOPURINE; PNEUMOCOCCAL CONJUGATED VACCINE; PNEUMOCOCCAL POLYSACCHARIDE VACCINE; PNEUMOCOCCUS VACCINE; POLYSACCHARIDE VACCINE; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; UNCLASSIFIED DRUG; 13-VALENT PNEUMOCOCCAL VACCINE; 23-VALENT PNEUMOCOCCAL CAPSULAR POLYSACCHARIDE VACCINE; BACTERIAL POLYSACCHARIDE; BACTERIUM ANTIBODY; TUMOR NECROSIS FACTOR ALPHA; VACCINE;

ADULT; ANTIBODY BLOOD LEVEL; ANTIBODY RESPONSE; ARM PAIN; ARTICLE; CONTROLLED STUDY; CROHN DISEASE; ENTEROCOCCAL INFECTION; FEMALE; FEVER; HEADACHE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MUSCLE RIGIDITY; NAUSEA; PHASE 4 CLINICAL TRIAL; PNEUMOCOCCAL INFECTION; PNEUMONIA; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; SEROTYPE; SINUSITIS; STOMACH PAIN; VACCINATION; ANTIBODY PRODUCTION; BLOOD; CLINICAL TRIAL; DRUG EFFECTS; IMMUNOLOGY; MIDDLE AGED; PNEUMOCOCCAL INFECTIONS; STREPTOCOCCUS PNEUMONIAE;

ADULT; ANTIBODIES, BACTERIAL; ANTIBODY FORMATION; CROHN DISEASE; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES; POLYSACCHARIDES, BACTERIAL; STREPTOCOCCUS PNEUMONIAE; TUMOR NECROSIS FACTOR-ALPHA; VACCINATION; VACCINES, CONJUGATE;

EID: 84941880296     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2015.08.011     Document Type: Article

References (30)

1. Loftus E.V. Clinical epidemiology of inflammatory bowel disease: incidence, prevalence, and environmental influences. Gastroenterology 2004, 126:1504-1517.
2. Baumgart D.C., Carding S.R. Inflammatory bowel disease: cause and immunobiology. Lancet 2007, 369:1627-1640.
3. Viget N., Vernier-Massouille G., Salmon-Ceron D., Yazdanpanah Y., Colombel J-F. Opportunistic infections in patients with inflammatory bowel disease: prevention and diagnosis. Gut 2008, 57:549-558.
4. Toruner M., Loftus E.V., Harmsen W.S., Zinsmeister A.R., Orenstein R., Sandborn W.J., et al. Risk factors for opportunistic infections in patients with inflammatory bowel disease. Gastroenterology 2008, 134:929-936.
5. Hutfless S.M., Weng X., Liu L., Allison J., Herrinton L.J. Mortality by medication use among patients with inflammatory bowel disease, 1996-2003. Gastroenterology 2007, 133:1779-1786.
6. Dave M., Purohit T., Razonable R., Loftus E.V. Opportunistic infections due to inflammatory bowel disease therapy. Inflamm Bowel Dis 2014, 20:196-212.
7. Rahier J.F., Ben-Horin S., Chowers Y., Conlon C., De Munter P., D'Haens G., et al. European evidence-based Consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. J Crohns Colitis 2009, 3:47-91.
8. Rahier J.F., Magro F., Abreu C., Armuzzi A., Ben-Horin S., Chowers Y., et al. Second European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. J Crohn's Colitis 2014, 8:443-468.
9. Wotton C.J., Goldacre M.J. Risk of invasive pneumococcal disease in people admitted to hospital with selected immune-mediated diseases: record linkage cohort analyses. J Epidemiol Community Health 2012, 66:1177-1181.
10. Kantsø B., Simonsen J., Hoffmann S., Valentiner-Branth P., Petersen A.M., Jess T. Tu1186 risk of invasive pneumococcal infection in patients with inflammatory bowel disease: a nationwide Danish cohort study. Gastroenterology 2014, 146. S-778.
11. Pollard A.J., Perrett K.P., Beverley P.C. Maintaining protection against invasive bacteria with protein-polysaccharide conjugate vaccines. Nat Rev Immunol 2009, 9:213-220.
12. Jackson L.A., Janoff E.N. Pneumococcal vaccination of elderly adults: new paradigms for protection. Clin Infect Dis 2008, 47:1328-1338.
13. Moberley S., Holden J., Tatham D.P., Andrews R.M. Vaccines for preventing pneumococcal infection in adults. Cochrane Database Syst Rev 2013, 1:CD000422.
14. Jackson L.A., Gurtman A., van Cleeff M., Jansen K.U., Jayawardene D., Devlin C., et al. Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine compared to a 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-naive adults. Vaccine 2013, 31:3577-3584.
15. Scott D.A., Komjathy S.F., Hu B.T., Baker S., Supan L.A., Monahan C.A., et al. Phase 1 trial of a 13-valent pneumococcal conjugate vaccine in healthy adults. Vaccine 2007, 25:6164-6166.
16. Musher D.M., Sampath R., Rodriguez-Barradas M.C. The potential role for protein-conjugate pneumococcal vaccine in adults: what is the supporting evidence?. Clin Infect Dis 2011, 52:633-640.
17. Lee C.K., Kim H.-S., Ye B.D., Lee K.-M., Kim Y.S., Rhee S.Y., et al. Patients with Crohn's disease on anti-tumor necrosis factor therapy are at significant risk of inadequate response to the 23-valent pneumococcal polysaccharide vaccine. J Crohns Colitis 2014, 8:384-391.
18. Fiorino G., Peyrin-Biroulet L., Naccarato P., Szabò H., Sociale O.R., Vetrano S., et al. Effects of immunosuppression on immune response to pneumococcal vaccine in inflammatory bowel disease: a prospective study. Inflamm Bowel Dis 2012, 18:1042-1047.
19. Melmed G.Y., Agarwal N., Frenck R.W., Ippoliti A.F., Ibanez P., Papadakis K.A., et al. Immunosuppression impairs response to pneumococcal polysaccharide vaccination in patients with inflammatory bowel disease. Am J Gastroenterol 2010, 105:148-154.
20. Harvey R.F., Bradshaw J.M. A simple index of Crohn's-disease activity. Lancet 1980, 1:514.
21. Lal G., Balmer P., Stanford E., Martin S., Warrington R., Borrow R. Development and validation of a nonaplex assay for the simultaneous quantitation of antibodies to nine Streptococcus pneumoniae serotypes. J Immunol Methods 2005, 296:135-147.
22. Pickering J.W., Martins T.B., Greer R.W., Schroder M.C., Astill M.E., Litwin C.M., et al. A multiplexed fluorescent microsphere immunoassay for antibodies to pneumococcal capsular polysaccharides. Am J Clin Pathol 2002, 117:589-596.
23. Concepcion N., Frasch C.E. Evaluation of previously assigned antibody concentrations in pneumococcal polysaccharide reference serum 89SF by the method of cross-standardization. Clin Diagn Lab Immunol 1998, 5:199-204.
24. Jackson L.A., Gurtman A., Rice K., Pauksens K., Greenberg R.N., Jones T.R., et al. Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in adults 70 years of age and older previously vaccinated with 23-valent pneumococcal polysaccharide vaccine. Vaccine 2013, 31:3585-3593.
25. Visser L.G. TNF-α antagonists and immunization. Curr Infect Dis Rep 2011, 13:243-247.
26. Elkayam O., Caspi D., Reitblatt T. The effect of tumor necrosis factor blockade on the response to pneumococcal vaccination in patients with rheumatoid arthritis and ankylosing spondylitis. Semin Arthritis Rheum 2004, 33:283-288.
27. Kapetanovic M.C., Saxne T., Sjöholm A., Truedsson L., Jönsson G., Geborek P. Influence of methotrexate, TNF blockers and prednisolone on antibody responses to pneumococcal polysaccharide vaccine in patients with rheumatoid arthritis. Rheumatology 2006, 45:106-111.
28. Dotan I., Werner L., Vigodman S., Agarwal S., Pfeffer J., Horowitz N., et al. Normal response to vaccines in inflammatory bowel disease patients treated with thiopurines. Inflamm Bowel Dis 2011, 18:261-268.
29. Siber G.R., Chang I., Baker S., Fernsten P., O'Brien K.L., Santosham M., et al. Estimating the protective concentration of anti-pneumococcal capsular polysaccharide antibodies. Vaccine 2007, 25:3816-3826.
30. Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among adults aged ≥65 years: recommendations of the advisory committee on immunization practices (ACIP). Morb Mortal Wkly Rep 2014, 63. Center for Disease Control and Prevention.